CD4 and cancer: No matter how much low the frequency of TILs in the pMMR CRC tumor microenvironment is prior to any therapy, their presence provides some insight concerning the role of the cancer immunity cycle activation phase to prime antigen-specific CD4+ and CD8+ T-cells.